Literature DB >> 23942561

[Secondary immunodeficiency in rheumatological diseases].

D Ernst1, R E Schmidt, T Witte.   

Abstract

Immunosuppressive treatment plays a crucial role in the management of autoimmune and autoinflammatory diseases. Knowledge about the ensuing immune deficits resulting from these therapies as well as common infections in immunocompromised patients should be familiar to all doctors involved in the prescription and administration of immunosuppressive drugs. Comprehensive pretreatment screening, regular monitoring both during and following treatment as well common sense preventive measures, such as vaccination can help further minimise the risk of infection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23942561     DOI: 10.1007/s00393-013-1160-7

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  41 in total

Review 1.  Immunizations in HIV-infected adults.

Authors:  Pablo Rivas; María Dolores Herrero; Sabino Puente; Germán Ramírez-Olivencia; Vincent Soriano
Journal:  AIDS Rev       Date:  2007 Jul-Sep       Impact factor: 2.500

2.  Cancer in systemic lupus: what drives the risk?

Authors:  Sasha Bernatsky; A E Clarke; R Ramsey-Goldman
Journal:  Cancer Causes Control       Date:  2008-06-25       Impact factor: 2.506

3.  Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis.

Authors:  Athina Pyrpasopoulou; Stella Douma; Themistoklis Vassiliadis; Sofia Chatzimichailidou; Areti Triantafyllou; Spyros Aslanidis
Journal:  Rheumatol Int       Date:  2009-10-15       Impact factor: 2.631

4.  Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study.

Authors:  Dongmei Ji; Junning Cao; Xiaonan Hong; Junmin Li; Jianmin Wang; Fangyuan Chen; Chun Wang; Shanhua Zou
Journal:  Eur J Haematol       Date:  2010-05-20       Impact factor: 2.997

Review 5.  Overview of safety of non-biologic and biologic DMARDs.

Authors:  Eric M Ruderman
Journal:  Rheumatology (Oxford)       Date:  2012-12       Impact factor: 7.580

6.  Initiation of rheumatoid arthritis treatments and the risk of serious infections.

Authors:  Carlos G Grijalva; Lisa Kaltenbach; Patrick G Arbogast; Edward F Mitchel; Marie R Griffin
Journal:  Rheumatology (Oxford)       Date:  2009-11-11       Impact factor: 7.580

Review 7.  [Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases].

Authors:  R Diel; B Hauer; R Loddenkemper; B Manger; K Krüger
Journal:  Pneumologie       Date:  2009-06-10

8.  Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry.

Authors:  Sanne A A van Dartel; Jaap Fransen; Wietske Kievit; Ellen A J Dutmer; Herman L M Brus; Nella M Houtman; Mart A F van de Laar; Piet L C M van Riel
Journal:  Rheumatology (Oxford)       Date:  2013-01-30       Impact factor: 7.580

9.  Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.

Authors:  Clifton O Bingham; R John Looney; Atul Deodhar; Neal Halsey; Maria Greenwald; Christine Codding; Benjamin Trzaskoma; Flavius Martin; Sunil Agarwal; Ariella Kelman
Journal:  Arthritis Rheum       Date:  2010-01

10.  Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients.

Authors:  Ronald F van Vollenhoven; Paul Emery; Clifton O Bingham; Edward C Keystone; Roy M Fleischmann; Daniel E Furst; Nicola Tyson; Neil Collinson; Patricia B Lehane
Journal:  Ann Rheum Dis       Date:  2012-11-07       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.